PIP Search Page

Displaying 21 - 40 of 173

PIPS Search Results
PIP Number	Active Substance Sort descending	Conditions / Indications	Invented Name	Therapeutic area	Decision Type	Compliance Check	Date Published
MHRA-100048-PIP01-21	Afamitresgene autoleucel	Treatment of soft tissue sarcoma	Not available at present.	Oncology	P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s)	No	17/03/2022
MHRA-100056-PIP01-21	BENRALIZUMAB	Eosinophilic gastritis (EG) and eosinophilic gastroenteritis (EGE)	FASENRA FASENRA FASENRA	Gastroenterology-Hepatology	P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s)	No	17/03/2022
MHRA-100057-PIP01-21	BENRALIZUMAB	Treatment of eosinophilic oesophagitis	FASENRA FASENRA FASENRA FASENRA	Gastroenterology-Hepatology	P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s)	No	17/03/2022
MHRA-100140-PIP01-21	BENRALIZUMAB	Treatment of Hypereosinophilic syndrome (HES)	FASENRA FASENRA FASENRA FASENRA FASENRA PEN FASENRA	Haematology-Hemostaseology	P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s)	No	17/05/2022
MHRA-100141-PIP01-21	BENRALIZUMAB	Treatment of Eosinophilic Granulomatosis with Polyangitis (EGPA)	FASENRA FASENRA FASENRA FASENRA FASENRA FASENRA PEN	Pneumology - Allergology	P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s)	No	27/09/2022
MHRA-100068-PIP01-21	VEDOLIZUMAB	Treatment of Pouchitis	Entyvio Entyvio Entyvio Entyvio Entyvio Entyvio Entyvio Entyvio Entyvio; Kynteles Entyvio Entyvio Entyvio Entyvio Entyvio Entyvio Entyvio Entyvio Entyvio Entyvio Entyvio Entyvio Entyvio Entyvio Entyvio Entyvio Entyvio Entyvio Entyvio Entyvio Entyvio Entyvio Entyvio Entyvio Entyvio Entyvio Entyvio Entyvio Entyvio Entyvio Entyvio Kynteles Entyvio Entyvio Entyvio Entyvio	Gastroenterology-Hepatology	P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s)	Yes	17/03/2022
MHRA-100060-PIP01-21	2'-O-(2-methoxyethyl) phosphorothioate antisense oligonucleotide targeting CD49d RNA	Treatment of Duchenne muscular dystrophy		Other: Neuromuscular	P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s)	No	17/03/2022
MHRA-100054-PIP01-21	RO7496998 (AT-527)	Treatment of coronavirus disease 2019 (COVID-19)	Not available at present	Infectious diseases Other: Pandemic	P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s)	No	18/03/2022
MHRA-100218-PIP01-21	DUPILUMAB	Treatment of chronic spontaneous urticaria	Dupixent Dupixent	Dermatology	P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s)	No	27/09/2022
MHRA-100118-PIP02-22	OCRELIZUMAB	Treatment of Multiple Sclerosis	Ocrevus Ocrevus Ocrevus	Neurology	P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s)	No	24/08/2023
MHRA-100164-PIP01-21	(1R,2S,5S)-N-((1S)-1-Cyano-2-((3S)-2-oxopyrrolidin-3-yl)ethyl)-3-((2S)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido)butanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide	Treatment of coronavirus disease 2019 (COVID-19) Prevention of coronavirus disease 2019 (COVID-19)	Not available at present	Infectious diseases	P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s)	No	18/03/2022
MHRA-100339-PIP01-21	Autologous selected renal cells	Treatment of Chronic Kidney Disease	Not available at present	Uro-Nephrology	P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s)	No	04/05/2022
MHRA-100196-PIP01-21	SARS-CoV-2 virus, beta-propiolactone inactivated	Prevention of coronavirus disease 2019 (COVID-19)	Not available	Vaccines	P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s)	No	17/05/2022
MHRA-100196-PIP01-21	SARS-CoV-2 virus, beta-propiolactone inactivated	Prevention of coronavirus disease 2019 (COVID-19)	Not available	Vaccines	P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s)	No	17/05/2022
MHRA-100150-PIP01-21	AZITHROMYCIN	Prevention of bronchopulmonary dysplasia (BPD)		Pneumology - Allergology Neonatology - Paediatric Intensive Care	P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s)	No	17/05/2022
MHRA-100106-PIP01-21	3,5-diamino-6-chloro-N-(N-(4-(4-(2-(hexyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)ethoxy)phenyl)butyl)-carbamimidoyl)pyrazine-2-carboxaminde sodium chloride solution 4.2% (w/v)	Treatment of primary ciliary dyskinesia		Pneumology - Allergology	P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s)	No	17/05/2022
MHRA-100232-PIP01-21	ALECTINIB	Treatment of malignant neoplasms (except haematopoietic and lymphoid tissue neoplasms)	Alecensa Alecensa	Oncology	P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s)	No	17/05/2022
MHRA-100179-PIP01-21	vemircopan	Treatment of paroxysmal nocturnal haemoglobinuria		Haematology-Hemostaseology	P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s)	No	17/05/2022
MHRA-100179-PIP01-21	vemircopan	Treatment of paroxysmal nocturnal haemoglobinuria		Haematology-Hemostaseology	P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s)	No	17/05/2022
MHRA-100291-PIP01-21	imetelstat	Treatment of acute myeloid leukaemia Treatment of Myelodysplastic Syndromes (MDS), including JMML		Oncology	P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s)	No	17/05/2022

Download XLSX

Search Filters: